AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

1-8. (Cancelled).

9. (Currently amended). A method for ~~prophylaxis~~ treatment or inhibition of migraine which comprises

administering a therapeutically effective amount of a selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors to a patient, wherein the selective dual antagonist is a single compound; and

treating or inhibiting migraine in a migraine patient or a patient who has been diagnosed to be migraine or in whom periodical attacks of migraine occur.

10. (Cancelled).

11. (Withdrawn). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors comprises:

a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and

b) a 5-HT_7 receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT_7 receptor.

12. (Previously presented). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors comprises a dual antagonistic compound

for the 5-HT_{2B} and 5-HT_7 receptors having a selective binding affinity to both of the 5-HT_{2B} and 5-HT_7 receptors.

13. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-HT_{2B} and 5-HT_7 receptors are respectively one-hundredth or less of those of each of α_1, M_1, D_2, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4 and 5-HT_6 receptors.

14. (Previously presented). The method of claim 9, wherein the binding affinities for the 5-$HT2_B$ and 5-HT_7 receptors are higher than those of each of α_1, M_1, D_2, 5-HT_{1A}, 5-HT_{1B}, 5-HT_3, 5-HT_4 and 5-HT_6 receptors.

15. (Previously presented). The method of claim 9, wherein the binding affinities for the 5-$HT2_B$ and 5-HT_7 receptors are higher than those of each of α_1, M_1, D_2, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4 and 5-HT_6 receptors.

16. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-$HT2_B$ and 5-HT_7 receptors are respectively one-tenth or less of those of each of α_1, M_1, D_2, 5-HT_{1A}, 5-HT_{1B}, 5-HT_3, 5-HT_4 and 5-HT_6 receptors.

17. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-$HT2_B$ and 5-HT_7 receptors are respectively one-tenth or less of those of each of α_1, M_1, D_2, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT_3, 5-HT_4 and 5-HT_6 receptors.

18. (Previously presented). The method of claim 9, wherein the Ki or IC_{50} values for the 5-HT_{2B} and 5-HT_7 receptors are respectively one-hundredth or less of those of each of α_1, M_1, D_2, 5-HT_{1A}, 5-HT_{1B}, 5-HT_3, 5-HT_4 and 5-HT_6 receptors.

19. (New). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT_7 receptors is N-(diaminomethylene)-9-hydroxy-9H-fluorene-2-carboxamide.